title: Advances in hepatitis C therapy: What is the current state - what come's next?
abstract: Chronic hepatitis C virus (HCV) infection affects 80-160 million people worldwide and is one of the leading causes of chronic liver disease. It is only a few years ago that standard treatment regimes were based on pegylated interferon alpha and ribavirin. However, treatment of HCV has undergone a revolutionary change in recent years. The admission of the nucleotide polymerase inhibitor Sofosbuvir enabled an interferon-free regimen with direct antiviral agents (DAA). Meanwhile seven DAAs are available and can be applied in several combinations for 8 to 24 wk depending on HCV genotype and patient characteristics such as cirrhosis and chronic renal failure. High rates of sustained virological response (SVR) rates can be achieved with these novel drugs. Even in difficult to treat populations such as patients with liver cirrhosis, HCV-human immunodeficiency virus co-infections, after liver transplantion, or with chronic kidney disease comparable high rates of SVR can be achieved. The anticipated 2(nd) generation DAAs are strikingly effective in patients so far classified as difficult to treat including decompensated liver cirrhosis or post-transplant patients. These 2(nd) generations DAAs will have higher resistance barriers, higher antiviral effects and a pan-genotypic spectrum. This review highlights the current state of the art of antiviral treatment in hepatitis C and gives an outlook for upcoming therapies.
authors.affiliation: Steffen Zopf, Andreas E Kremer, Markus F Neurath, Juergen Siebler, Medical Department 1, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
authors.forename: Steffen
authors.initials: S
authors.lastname: Zopf
authors.affiliation: Steffen Zopf, Andreas E Kremer, Markus F Neurath, Juergen Siebler, Medical Department 1, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
authors.forename: Andreas E
authors.initials: AE
authors.lastname: Kremer
authors.affiliation: Steffen Zopf, Andreas E Kremer, Markus F Neurath, Juergen Siebler, Medical Department 1, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
authors.forename: Markus F
authors.initials: MF
authors.lastname: Neurath
authors.affiliation: Steffen Zopf, Andreas E Kremer, Markus F Neurath, Juergen Siebler, Medical Department 1, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
authors.forename: Juergen
authors.initials: J
authors.lastname: Siebler
keywords: Cirrhosis; Direct antiviral agents; Hepatitis C virus; Liver transplantation; Renal impairment; Sustained virological response
references.citation: Lancet. 2015 Jun 20;385(9986):2502-9
references.pmid: 25837829
references.citation: JAMA. 2015 May 5;313(17):1736-44
references.pmid: 25942724
references.citation: Clin Microbiol Infect. 2011 Feb;17(2):107-15
references.pmid: 21091831
references.citation: N Engl J Med. 2014 May 15;370(20):1879-88
references.pmid: 24720702
references.citation: N Engl J Med. 2011 Jun 23;364(25):2417-28
references.pmid: 21696308
references.citation: N Engl J Med. 2011 Mar 31;364(13):1195-206
references.pmid: 21449783
references.citation: Lancet. 2015 Mar 21;385(9973):1075-86
references.pmid: 25467591
references.citation: J Hepatol. 2013 Apr;58(4):646-54
references.pmid: 23178977
references.citation: JAMA. 2015 Mar 24-31;313(12):1232-9
references.pmid: 25706232
references.citation: N Engl J Med. 2014 May 15;370(20):1889-98
references.pmid: 24725239
references.citation: J Hepatol. 2011 Aug;55(2):245-64
references.pmid: 21371579
references.citation: J Hepatol. 2015 May;62(5):1008-14
references.pmid: 25445400
references.citation: J Hepatol. 2015 May;62(5):1040-6
references.pmid: 25450208
references.citation: N Engl J Med. 2014 Apr 17;370(16):1560-1
references.pmid: 24738674
references.citation: N Engl J Med. 2014 Apr 17;370(16):1483-93
references.pmid: 24725238
references.citation: Semin Liver Dis. 2014 Feb;34(1):9-21
references.pmid: 24782254
references.citation: Lancet. 2015 Oct 17;386(10003):1537-45
references.pmid: 26456905
references.citation: N Engl J Med. 2014 May 22;370(21):1993-2001
references.pmid: 24795201
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: N Engl J Med. 2014 Dec 18;371(25):2375-82
references.pmid: 25386767
references.citation: Gut. 2015 Jun;64(6):948-56
references.pmid: 25080450
references.citation: N Engl J Med. 2013 May 16;368(20):1878-87
references.pmid: 23607594
references.citation: J Hepatol. 2014 Aug;61(2):373-95
references.pmid: 24818984
references.citation: JAMA. 2015 May 5;313(17):1728-35
references.pmid: 25942723
references.citation: N Engl J Med. 2014 Apr 24;370(17):1604-14
references.pmid: 24720679
references.citation: N Engl J Med. 2014 May 22;370(21):1973-82
references.pmid: 24725237
references.citation: N Engl J Med. 2014 Apr 24;370(17):1594-603
references.pmid: 24720703
references.citation: Liver Int. 2010 Mar;30(3):342-55
references.pmid: 20015149
references.citation: N Engl J Med. 2014 May 22;370(21):1983-92
references.pmid: 24795200
references.citation: N Engl J Med. 2013 Jan 3;368(1):34-44
references.pmid: 23281974
references.citation: Hepatology. 2015 Apr;61(4):1127-35
references.pmid: 25614962
references.citation: Lancet. 2014 Nov 15;384(9956):1756-65
references.pmid: 25078309
references.citation: Gastroenterology. 2014 Aug;147(2):359-365.e1
references.pmid: 24818763
references.citation: Hepatology. 2015 Sep;62(3):932-54
references.pmid: 26111063
references.citation: Gastroenterology. 2015 Sep;149(3):649-59
references.pmid: 25985734
references.citation: Lancet. 2015 Mar 21;385(9973):1107-13
references.pmid: 25591505
references.citation: Gastroenterology. 2015 Jan;148(1):100-107.e1
references.pmid: 25261839
references.citation: N Engl J Med. 2011 Mar 31;364(13):1207-17
references.pmid: 21449784
references.citation: N Engl J Med. 2013 May 16;368(20):1867-77
references.pmid: 23607593